• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1119713 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type- `0 q3 f2 \" `  \
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 $ V! [# b7 j  u5 y( @/ R# {
+ Author Affiliations6 {) R+ Z8 u& c

+ G% @1 y. ^8 F/ g/ m/ [+ P& |( J1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan + y9 d2 v" V0 O! A4 P$ g; {
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
2 F( T8 c/ X6 q& E4 G2 Y) @3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan # V  D& Q9 H: ?. Q* H( i
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
7 C) A1 b: z" w( F8 d* g, T; Q5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
) L( ], I( A- `! f7 a6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan : z+ w# m' J( U0 k8 z3 B6 U
7Kinki University School of Medicine, Osaka 589-8511, Japan 7 f% B- L/ H# c, l
8Izumi Municipal Hospital, Osaka 594-0071, Japan : l" D1 {! r' ~6 h. c9 i
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan " o% D& }( V0 _  ^4 l
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; Q; B# q/ a. ]/ w$ E" C* n6 T
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
; s+ }, i+ G" r% j( f: _# [7 C: G; v+ I/ l# E$ c; N$ H4 l
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
, d1 v( a' y/ r6 a- b# L8 Q) Q8 s1 q
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato * i7 I' `# A) W: |: D2 B4 w

8 M% I9 S* R: z; _2 Q( Z) oAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  2 ?% C! `/ h3 [7 B( k
* J6 I/ M4 C0 j7 Z& i
Published online on: Thursday, December 1, 2011 5 w2 Q$ c# a' B$ n, z7 v- }5 e/ T
3 ?- L% S; K$ u. f; [
Doi: 10.3892/ol.2011.507
4 g5 D7 Z1 A8 R  e
2 K/ `  Z# i1 o+ p4 h- @! q+ @Pages: 405-410 $ V& {! f+ s4 I4 R
6 {: o6 K( G: T9 k+ y5 k! J# S, y
Abstract:6 y+ D) y) _/ n  c) L
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.7 w! \4 S. {% t: `5 M$ \
' n" s/ u, ?+ J* W8 }8 l5 j
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population/ v9 O% Q3 O2 S% L* m
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 / s2 u" \, t5 ]2 q; O/ z
+ Author Affiliations2 i; n9 f: n. F; H: ?$ W
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu - g) c" n& |1 ~5 v$ C! B8 T
2Department of Thoracic Surgery, Kyoto University, Kyoto
; h, |  N  q# L2 ^6 H# Z) y7 s3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
# r3 v8 @/ D2 O# W8 Z/ p9 k&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp ( \$ }$ ^! d: Y9 `
Received September 3, 2010.
3 t1 R! \% P7 h) k( a; q0 mRevision received November 11, 2010.
" \8 J3 u8 o5 u% }  |; gAccepted November 17, 2010. 4 o: Z4 U& F+ ~4 C4 p+ ^/ ]) t: J
Abstract( c+ {1 e+ c  O4 \5 U: @
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. $ ]2 a& X  q6 n7 i, \- g' V
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. - Q9 ?6 p) `) X1 R/ a
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 1 f" P% G9 \* W0 |0 e
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. + q! Q1 D# a) U. K& _3 S, ?' N
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。8 @- m7 {! t- |: D& d% C
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?! z" u) O! ^. k
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
3 o1 b4 b1 v4 v7 E6 O: phttp://clinicaltrials.gov/ct2/show/NCT01523587; a- @; e$ F' g8 e4 l8 D

2 i* j6 d' d) a( A: oBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC* T, r! R8 O6 V; V$ [
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 : t) Z: ?' W9 J) J
9 T4 W' X7 m9 e4 J1 l: n& x
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
/ m4 |7 D0 U8 d  f0 ~至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
& d  f4 U- B5 X$ R  F( [' U+ ?( f从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
  G0 \8 w+ d7 D8 x+ V) A8 y* L至今为止,未出 ...

, }* y* |" A, }2 E2 f* F7 k没有副作用是第一追求,效果显著是第二追求。
& D. ^; B6 C0 ]7 k$ i$ k  d不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表